NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$319.21
-1.90 (-0.59%)
Close of Nov 06, 2026 · end-of-day data
PEN 8-K filings in 2023
Every material Form 8-K Penumbra filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Penumbra reported third-quarter 2023 results, with revenue up 26.8% from a year earlier and GAAP net income of $9.2 million, compared with a net loss of $2.3 million in the third quarter of 2022. The company also said it expects fourth-quarter revenue growth of 28% to 31% and cited full-year 2023 revenue guidance of $1.05 billion to $1.07 billion.
Q3 2023 revenue was $270.9 million, up 26.8% (25.9% in constant currency) from $213.7 million in Q3 2022.
GAAP income from operations was $12.6 million, including a one-time $18.2 million acquired in-process R&D expense; non-GAAP income from operations was $33.2 million.
Thrombectomy product revenue rose 38.0% to $179.1 million, a company record.
Full-year 2023 revenue guidance is $1.05 billion to $1.07 billion, with fourth-quarter growth expected at 28% to 31%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Penumbra filing is on SEC EDGAR ↗. 8-K briefs of other companies →